Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
| dc.contributor.author | Thuss-Patience, P | |
| dc.contributor.author | Shah, M | |
| dc.contributor.author | Ohtsu, A | |
| dc.contributor.author | Van Cutsem, E | |
| dc.contributor.author | Ajani, J | |
| dc.contributor.author | Castro, H | |
| dc.contributor.author | Mansoor, Was | |
| dc.contributor.author | Chung, H | |
| dc.contributor.author | Bodoky, G | |
| dc.contributor.author | Shitara, K | |
| dc.contributor.author | Phillips, G | |
| dc.contributor.author | van der Horst, T | |
| dc.contributor.author | Harle-Yge, M | |
| dc.contributor.author | Althaus, B | |
| dc.contributor.author | Kang, Y | |
| dc.date.accessioned | 2017-04-19T17:09:04Z | |
| dc.date.available | 2017-04-19T17:09:04Z | |
| dc.date.issued | 2017-03-23 | |
| dc.identifier.citation | Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. 2017, Lancet Oncol | en |
| dc.identifier.issn | 1474-5488 | |
| dc.identifier.pmid | 28343975 | |
| dc.identifier.doi | 10.1016/S1470-2045(17)30111-0 | |
| dc.identifier.uri | http://hdl.handle.net/10541/620260 | |
| dc.description.abstract | Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is no established therapy in the second-line setting. In GATSBY, we examined the efficacy and tolerability of trastuzumab emtansine in patients previously treated for HER2-positive advanced gastric cancer (unresectable, locally advanced, or metastatic gastric cancer, including adenocarcinoma of the gastro-oesophageal junction). | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to The Lancet. Oncology | en |
| dc.title | Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. | en |
| dc.type | Article | en |
| dc.contributor.department | Department of Hematology, Oncology, and Tumor Immunology, Charite-University Medicine Berlin, Berlin, Germany | en |
| dc.identifier.journal | The Lancet. Oncology | en |
| html.description.abstract | Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is no established therapy in the second-line setting. In GATSBY, we examined the efficacy and tolerability of trastuzumab emtansine in patients previously treated for HER2-positive advanced gastric cancer (unresectable, locally advanced, or metastatic gastric cancer, including adenocarcinoma of the gastro-oesophageal junction). |